Payment overview · 2025
General Payments
$427.86
23 reported records · 9 companies
Healthcare provider profile · identity verified
Edwin Oscar Byrd, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WOODRUFF, SC · NPI 1891775516
Verified facts
What the public records show
CMS Open Payments records show Edwin Oscar Byrd, M.D. received $427.86 in general payments during 2025 across 23 reported records.
Kowa Pharmaceuticals America, Inc. accounted for 34.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $147.90 | 34.6% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.76 | 15.6% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.70 | 12.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $37.97 | 8.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.82 | 8.1% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $31.36 | 7.3% | 2 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $21.84 | 5.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.79 | 4.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.72 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $427.86 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $147.90 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $66.76 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.70 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $37.97 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $34.82 | 2 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $31.36 | 2 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lorazepam | Lorazepam | 196 | 27 |
| Lisinopril | Lisinopril | 166 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 160 | 42 |
| Gabapentin | Gabapentin | 160 | 33 |
| Metformin Hcl | Metformin Hcl | 155 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 140 | 43 |
| Omeprazole | Omeprazole | 120 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 116 | 33 |
| Alprazolam | Alprazolam | 110 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 27 |
| Meloxicam | Meloxicam | 107 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 18 |
| Trazodone Hcl | Trazodone Hcl | 78 | 17 |
| Losartan Potassium | Losartan Potassium | 76 | 18 |
| Glimepiride | Glimepiride | 74 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 74 | 22 |
| Celecoxib | Celecoxib | 71 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 22 |
| Simvastatin | Simvastatin | 67 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 18 |
| Clonazepam | Clonazepam | 65 | suppressed |
| Ibuprofen | Ibuprofen | 63 | 19 |
| Estradiol | Estradiol | 55 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 14 |
| Prednisone | Prednisone | 55 | 18 |
| Famotidine | Famotidine | 54 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 11 |
| Carvedilol | Carvedilol | 50 | 16 |
| Tramadol Hcl | Tramadol Hcl | 50 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 12 |
| Diazepam | Diazepam | 46 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 46 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 15 |
| Furosemide | Furosemide | 44 | 15 |
| Eliquis | Apixaban | 43 | suppressed |
| Ozempic | Semaglutide | 43 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 13 |
| Azithromycin | Azithromycin | 35 | 31 |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 14 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 15 |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 14 |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 11 |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Ethosuximide | Ethosuximide | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $427.86 · 23 records | Kowa Pharmaceuticals America, Inc. | AIRSUPRA, Doc Band, Jornay PM, Ozempic, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, VOQUEZNA, XIFAXAN, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error